Department of Pharmacy, JR Sapporo Hospital, Sapporo, Japan.
Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo, Japan.
In Vivo. 2024 Jan-Feb;38(1):453-459. doi: 10.21873/invivo.13459.
BACKGROUND/AIM: In recent years, the Geriatric Nutritional Risk Index (GNRI) has been reported as a predictor of prognosis in many patients with cancer. This study investigated the association of preoperative GNRI with the occurrence of adverse events and duration of treatment with capecitabine plus oxaliplatin (CAPOX), a postoperative adjuvant chemotherapy, in 59 patients with colorectal cancer from September 2019 to April 2022.
A cut-off value of 100.9 was used to categorize patients into high and low GNRI groups.
The incidence of grade ≥2 leukopenia (p=0.03), and all grades peripheral neuropathy (p=0.04) were significantly more frequent in the low GNRI group. Analysis of factors influencing treatment duration by univariate and multivariate Cox regression proportional hazards models showed a significant difference in GNRI (p=0.0097).
GNRI, a nutritional indicator assessed before the start of treatment, influences the occurrence of adverse events and duration of treatment with CAPOX as adjuvant chemotherapy. To complete CAPOX therapy, preoperatively, it is important to assess the patients' nutritional status using the GNRI and to actively intervene in nutritional therapy.
背景/目的：近年来，老年营养风险指数（GNRI）已被报道可作为许多癌症患者预后的预测指标。本研究调查了术前 GNRI 与 2019 年 9 月至 2022 年 4 月 59 例结直肠癌患者接受卡培他滨加奥沙利铂（CAPOX）术后辅助化疗时不良事件的发生和治疗持续时间的关系。
使用 100.9 的截断值将患者分为高 GNRI 组和低 GNRI 组。
低 GNRI 组的≥2 级白细胞减少症（p=0.03）和所有级别的周围神经病变（p=0.04）发生率显著更高。单因素和多因素 Cox 比例风险回归分析显示，GNRI 对治疗持续时间有显著影响（p=0.0097）。
GNRI 是治疗前评估的营养指标，影响 CAPOX 作为辅助化疗的不良事件发生和治疗持续时间。为了完成 CAPOX 治疗，在术前使用 GNRI 评估患者的营养状况，并积极进行营养治疗非常重要。
